Insider Transactions Reported by 9 Insiders of Lipocine Inc.

Symbol
LPCN on Nasdaq
Location
Salt Lake City, United States

There are no Buy or Sell transactions made by insiders since 19 Mar 2025

Lipocine Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Mahesh V Patel Chief Executive Officer, Director $1,461,344 02 Jan 2026
Krista Fogarty Principal Accounting Officer $168,613 18 Dec 2025
Morgan R. Brown Chief Financial Officer $46,746 07 Dec 2021
Richard Dana Ono Director $36,883 04 Jun 2025
Jeffrey Arvin Fink Director $36,883 04 Jun 2025
John W. Higuchi Director $36,883 04 Jun 2025
George Nomikos Chief Medical Officer $33,200 01 Nov 2022
Spyros Papapetropoulos Director $22,956 04 Jun 2025
Jill M. Jene Director $22,956 04 Jun 2025

Recent Insider Transactions by Companies or Individuals for Lipocine Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Mahesh V Patel LPCN Stock Option (Right to Buy) Award 15.9% 25,000 182,668 02 Jan 2026 Direct
Mahesh V Patel LPCN Stock Option (Right to Buy) Award 5.79% 8,629 157,668 18 Dec 2025 Direct
Krista Fogarty LPCN Stock Option (Right to Buy) Award 107.4% 20,786 40,146 18 Dec 2025 Direct
Richard Dana Ono LPCN Common Stock (Right to Buy) Award 18.1% 1,764 11,526 04 Jun 2025 Direct
Jill M. Jene LPCN Stock Option (Right to Buy) Award 32.6% 1,764 7,174 04 Jun 2025 Direct
Spyros Papapetropoulos LPCN Stock Option (Right to Buy) Award 32.6% 1,764 7,174 04 Jun 2025 Direct
Jeffrey Arvin Fink LPCN Common Stock (Right to Buy) Award 18.1% 1,764 11,526 04 Jun 2025 Direct
John W. Higuchi LPCN Common Stock (Right to Buy) Award 18.1% 1,764 11,526 04 Jun 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.